NEXGEL and STADA Launch Histasolv, Europe's Top DAO Enzyme Supplement, in North America

NEXGEL and STADA have partnered to introduce Histasolv, the top-selling DAO enzyme supplement in Europe, to North America. Histasolv, treating histamine food intolerance, stands out for its innovative formulation, with superior potency and stability. NEXGEL will begin direct-to-consumer sales in Q3 2024, marking STADA's expansion into the North American market with a trusted partner.

Introduction:
NEXGEL, Inc., a leading provider of medical and over-the-counter (OTC) products, and STADA Arzneimittel AG, a European leader in consumer health, have recently announced a partnership to introduce Histasolv, the top-selling DAO enzyme supplement in Europe for histamine food intolerance, to the North American market. This partnership marks STADA's expansion into the North American market with a trusted partner (1).

Background on Histasolv:
Histasolv is a game-changing supplement formulated to address histamine food intolerance, a common issue affecting an estimated 20% of the population (2). Its innovative composition boasts superior potency and stability, making it an excellent choice for individuals seeking relief from histamine-related symptoms (3).

Partnership Details:
NEXGEL will begin direct-to-consumer sales of Histasolv in Q3 2024, marking STADA's entry into the North American market with a reputable partner. The collaboration between NEXGEL and STADA is expected to yield a product launch in mid-2024, providing North American consumers with an established European product (1).

Company Overviews:
NEXGEL, based in Langhorne, Pennsylvania, has specialized in the development and manufacturing of electron-beam, cross-linked hydrogels for over two decades. The company's diverse range of brands includes Silverseal, Hexagels, Turfguard, Kenkoderm, and Dermablock (1).

STADA Arzneimittel AG, headquartered in Bad Vilbel, Germany, focuses on a three-pillar strategy consisting of consumer healthcare products, generics, and specialty pharma. With a global presence in approximately 120 countries, the company reported group sales of EUR 3,797.2 million and earnings before interest, taxes, depreciation, and amortization (EBITDA) of EUR 884.7 million in financial year 2022 (1).

Future Outlook:
The partnership between NEXGEL and STADA has the potential to significantly impact the North American market for histamine food intolerance supplements. As the demand for effective solutions grows, this collaboration is expected to contribute to the overall growth and success of both companies (1).

References:
1. NEXGEL, Inc. Press Release. NEXGEL Announces Partnership with STADA to Distribute and Commercialize Consumer Health OTC Products in North America. Dec 11, 2023. https://ir.nexgel.com/news-events/press-releases/detail/63/nexgel-announces-partnership-with-stada-to-distribute-and
2. Statista. Prevalence of histamine intolerance in the United States. https://www.statista.com/statistics/1125701/histamine-intolerance-prevalence-in-the-us/
3. NEXGEL, Inc. Press Release. NEXGEL Announces Partnership with STADA to Distribute and Commercialize Consumer Health OTC Products in North America. Dec 11, 2023. https://www.nasdaq.com/press-release/nexgel-announces-partnership-with-stada-to-distribute-and-commercialize-consumer-health-otc-products-in-north-america-2023-12-11